1. Number of persons with symptomatic knee osteoarthritis in the US: Impact of race and ethnicity, age, sex, and obesity;Deshpande;Arthritis Care Res,2016
2. Leyland KM, Gates LS, Sanchez-Santos MT, et al. White paper: osteoarthritis and mortality IPD meta-analysis. In: Osteoarthritis Research Society International (OARSI). white paper: osteoarthritis: a serious disease; December 1, 2016. Submitted to the US Food and Drug Administration. 〈https://www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf〉 [accessed July 20, 2024].
3. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis;Geenen;Ann Rheum Dis,2018
4. National Institute for Health and Care Excellence. Osteoarthritis. Care and management in adults. Clinical guideline CG177; 2014. Available: 〈https://www.nice.org.uk/guidance/cg177/evidence/full-guideline-pdf-191761311〉 [Accessed July 20, 2024].
5. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period;Berenbaum;Ann Rheum Dis,2020